Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Immunocore
About
Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.
- Abingdon,Oxfordshire,United Kingdom
- 251 - 500
- http://immunocore.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $140M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2008
- Number Of Employee
- 251 - 500
- Operating Status
- Active
- Stock Symbol
- nasdaq:IMCR
- Legal Name
- Immunocore Limited
Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 18, 2022 | Post-IPO Equity | $140M | 3 | — | — | Detail |
| Feb 4, 2021 | IPO | $258.31M | — | — | — | Detail |
| Jan 11, 2021 | Series C | $75M | 1 |
BlackRock
|
— | Detail |
| Jan 11, 2021 | Debt Financing | $100M | 1 |
|
— | Detail |
| Mar 2, 2020 | Series B | $130M | 9 |
General Atlantic
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
BlackRock
|
Yes | Series C |
|
|
Yes | Debt Financing |
Woodford Investment Management
|
Yes | Series A |
|
|
Yes | Grant |
|
General Atlantic
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
RTW Investments
|
— | Post-IPO Equity |
Bill & Melinda Gates Foundation
|
— | Series B |
CCB International
|
— | Series B |
Eli Lilly
|
— | Series B |
Employee Profiles
